J. Smeets

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial

Hein Putter, Christos Markopoulos, Annette Hasenburg, 2011, The Lancet.

Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer.

H. Putter, R. Paridaens, C. Seynaeve, 2009 .

Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial.

H. Putter, D. Rea, R. Paridaens, 2017, The Lancet. Oncology.

Five Years of Exemestane as Initial Therapy Compared to 5 Years of Tamoxifen Followed by Exemestane: The TEAM Trial, a Prospective, Randomized, Phase III Trial in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer.

H. Putter, R. Paridaens, C. Seynaeve, 2009 .

A randomized comparative trial of combined versus alternating therapy with cytostatic drugs and high‐dose medroxyprogesteron acetate in advanced breast cancer

L. Beex, H. Bron, J. Wils, 1985, Cancer.